Coherus Oncology (CHRS) Non-Current Assets (2016 - 2025)
Historic Non-Current Assets for Coherus Oncology (CHRS) over the last 13 years, with Q3 2025 value amounting to $55.6 million.
- Coherus Oncology's Non-Current Assets fell 5913.69% to $55.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $282.7 million, marking a year-over-year decrease of 4793.84%. This contributed to the annual value of $107.0 million for FY2024, which is 3053.98% down from last year.
- As of Q3 2025, Coherus Oncology's Non-Current Assets stood at $55.6 million, which was down 5913.69% from $59.3 million recorded in Q2 2025.
- In the past 5 years, Coherus Oncology's Non-Current Assets registered a high of $154.0 million during Q4 2023, and its lowest value of $55.6 million during Q3 2025.
- Its 5-year average for Non-Current Assets is $95.8 million, with a median of $86.5 million in 2023.
- As far as peak fluctuations go, Coherus Oncology's Non-Current Assets surged by 5730.4% in 2024, and later plummeted by 5913.69% in 2025.
- Coherus Oncology's Non-Current Assets (Quarter) stood at $77.0 million in 2021, then rose by 29.35% to $99.6 million in 2022, then soared by 54.57% to $154.0 million in 2023, then tumbled by 30.54% to $107.0 million in 2024, then tumbled by 48.05% to $55.6 million in 2025.
- Its Non-Current Assets stands at $55.6 million for Q3 2025, versus $59.3 million for Q2 2025 and $60.9 million for Q1 2025.